The peak of venture investment for digital health was in 2020 and 2021, precipitously declining later in 2022. And the outlook for 2023 is practical and Show-Me: that is, demonstrate clinical outcomes and return-on-investment before “I” (for investors) can take a leap of faith to spend a dollar, a Yen, a Euro, or British pound on a shiny new-new healthcare thing.
If it’s January, then CES and JP Morgan convene their influential annual meetings which feature health technology for globally engaged health industry stakeholders — investors, surely, but also providers, innovators, analysts, and insurers.
In my January 2023 column for Medecision. I weave the pragmatic story together based on datapoints from JP Morgan’s 2023 annual healthcare meeting in San Francisco and CES 2023 held in Las Vegas the previous week.
Check out the full plotline here on the Medecision blog portal.





Thanks to Jennifer Castenson for
Jane joined host Dr. Geeta "Dr. G" Nayyar and colleagues to brainstorm the value of vaccines for public and individual health in this challenging environment for health literacy, health politics, and health citizen grievance.
I'm grateful to be part of the Duke Corporate Education faculty, sharing perspectives on the future of health care with health and life science companies. Once again, I'll be brainstorming the future of health care with a cohort of executives working in a global pharmaceutical company.